Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes.
Abstract: Polar interactions in D30N are maintained, in agreement with the observed urea sensitivity.
Abstract: The side-chain variations at residue 30 relative to wild-type are the largest in D30N and the changes are consistent with the altered activity observed with peptide substrates.
Abstract: The side-chains of D30N and N88D are linked through a water molecule suggesting correlated changes at the two sites, as seen with clinical inhibitors.
Abstract: We have determined crystal structures of HIV-1 protease mutants, D30N, K45I, N88D, and L90M complexed with peptide inhibitor analogues of CA-p2 and p2-
PMID: 11391173
2001
Journal of acquired immune deficiency syndromes (1999)
Abstract: The prevalence of mutations associated with resistance to ARV drugs was: 29 (42.6%) to zidovudine, 10 (14.7%) to lamivudine, one (1.5%) to didanosine, one K103N mutation (associated with resistance to delavirdine, nevirapine, and efavirenz), one Y181C mutation (associated with resistance to delavirdine and nevirapine), two to both indinavir (M46I/L and V82A) and saquinavir (G48V and L90M), and one each to ritonavir (V82A) and nelfinavir (D30N).
Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina.
Abstract: In the viral protease region, 1/86 (1.2%) individuals carried the D30N mutation, whereas 1/85 (1.2%) had the M41L mutation in the reverse transcriptase (RT) region.
Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.
PMID: 11427587
2001
Journal of clinical microbiology
Abstract: D30N, M46I, V82A/F, and I84V were seen rarely.
Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations.
Abstract: The least fit viruses were associated with the RT mutation M184I/V (11.6% less fit) and the PR mutations D30N (12.4% less fit) and M46I/L (21% less fit).
DPC 681 and DPC 684: potent, selective inhibitors of human immunodeficiency virus protease active against clinically relevant mutant variants.
PMID: 11600351
2001
Antimicrobial agents and chemotherapy
Abstract: DPC 681 and DPC 684 showed no loss in potency toward recombinant mutant HIVs with the D30N mutation and a fivefold or smaller loss in potency toward mutant variants with three to five amino acid substitutions.
Emergence of drug resistance mutations in a group of HIV-infected children taking nelfinavir-containing regimens.
PMID: 11602042
2001
AIDS research and human retroviruses
Abstract: PI resistance mutations occurred in eight patients: D30N in six, and L90M in three.
Nelfinavir: an update on its use in HIV infection.
Abstract: Nelfinavir primarily selects for the D30N mutation, which is not seen with other protease inhibitors, and alone does not cause resistance to other protease inhibitors in vitro.
Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection.
Abstract: Two percent (1/48) had a major mutation associated with resistance to protease inhibitors (D30N).
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
PMID: 10915071
2000
The Journal of infectious diseases
Abstract: M184V preceded D30N in all determinable instances.
Abstract: All 6 PR-RT(+) patients had virus with M184V (lamuvidine resistance); 3 isolates also contained D30N (nelfinavir resistance).
HIV mutation literature information.
PMID: 
2001
Proteins
Browser Board
Co-occurred Entities
Filtrator
ViMRT